U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07276074) titled 'Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals' on March 28.
Brief Summary: Antithrombin (AT) is a physiological inhibitor of the coagulation cascade. In therapeutics, its presence in sufficient quantities is necessary for the pharmacological activity of unfractionated heparin (UFH) and partially low-molecular-weight heparin (LMWH).
In intensive care, patients are mostly treated with anticoagulants for either preventive or curative purposes, particularly for those whose care requires renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO), or cardiopulmonary bypass (...